Dr. Huda S. Salman
Claim this profileIndiana University Melvin and Bren Simon Comprehensive Cancer Center
Affiliated Hospitals
Indiana University Melvin And Bren Simon Comprehensive Cancer Center
Stony Brook Cancer Center
Clinical Trials Huda S. Salman is currently running
Combination Therapy
for Multiple Myeloma
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
Recruiting
2 awards
Phase 3
32 criteria
CAR T Cell Therapy
for Chronic Myelomonocytic Leukemia
This study is designed as a single arm open label traditional Phase I, 3+3, study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory CMML. Specifically, the study will evaluate the safety and feasibility of CD4CAR T-cells.
Recruiting
1 award
Phase 1
9 criteria
More about Huda S. Salman
Clinical Trial Related
4 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Huda S. Salman has experience with
- CD4CAR
- Dexamethasone
- Lenalidomide
- Duvelisib
- Bortezomib
- Daratumumab And Hyaluronidase-fihj
Breakdown of trials Huda S. Salman has run
T-Cell Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Huda S. Salman specialize in?
Huda S. Salman focuses on Lymphoma and T-Cell Lymphoma. In particular, much of their work with Lymphoma has involved CD4 positive patients, or patients who are undergoing treatment.
Is Huda S. Salman currently recruiting for clinical trials?
Yes, Huda S. Salman is currently recruiting for 4 clinical trials in Indianapolis Indiana. If you're interested in participating, you should apply.
Are there any treatments that Huda S. Salman has studied deeply?
Yes, Huda S. Salman has studied treatments such as CD4CAR, Dexamethasone, Lenalidomide.
What is the best way to schedule an appointment with Huda S. Salman?
Apply for one of the trials that Huda S. Salman is conducting.
What is the office address of Huda S. Salman?
The office of Huda S. Salman is located at: Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana 46202 United States. This is the address for their practice at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.